atai Life Sciences
 | |
| NASDAQ: ATAI | |
| Industry | Pharmaceutical; Psychedelic medicine |
| Founded | 2018 |
| Headquarters | , |
Key people | Christian Angermayer, Florian Brand, Lars Christian Wilde, Srinivas Rao |
| Website | atai Life Sciences |
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions.[1][2][3][4][5] It was founded in 2018 and is headquartered in Berlin, Germany.[1][5]
The company's pharmaceutical candidates include dimethyltryptamine (DMT; VLS-01), (R)-midomafetamine ((R)-MDMA; EMP-01), and ibogaine (IBX-210, DMX-1002), as well as EGX-121 (a non-tryptamine new chemical entity), 5-MeO-DMT (BPL-003), psilocin (ELE-101), inidascamine (RL-007), deuterated mitragynine (KUR-101), EGX-A, EGX-B, deuterated etifoxine (GRX-917), and arketamine (PCN-101).[4][3][6]
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange.[1][7] In January 2023, atai Life Science's leading drug candidate at the time, arketamine (PCN-101), failed to meet its primary endpoint in a clinical trial.[1] Following that, the company laid off 30% of its staff.[1]
Peter Thiel is a major investor in the company.[1] atai Life Sciences has a 22.4% stake in Compass Pathways.[1][5]
References
[edit]- ^ a b c d e f g Aday, Jacob S.; Barnett, Brian S.; Grossman, Dan; Murnane, Kevin S.; Nichols, Charles D.; Hendricks, Peter S. (1 September 2023). "Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry" (PDF). Psychedelic Medicine. 1 (3): 150–165. doi:10.1089/psymed.2023.0013. ISSN 2831-4425.
- ^ Grinstein, Jonathan D. (7 April 2023). "Go Higher: Atai Life Sciences Is Moving the Dial on Psychedelic Medicine Clinical Trial Outcomes". GEN - Genetic Engineering and Biotechnology News. Retrieved 27 February 2025.
- ^ a b "Delving into the Latest Updates on ATAI Life Sciences AG with Synapse". Synapse. 23 January 2025. Retrieved 27 February 2025.
- ^ a b "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 27 February 2025.
- ^ a b c "ATAI Life Sciences". Psychedelic Alpha. 6 October 2023. Retrieved 27 February 2025.
- ^ "Programs". atai Life Sciences. 13 January 2025. Retrieved 27 February 2025.
- ^ Ponieman, Natan (14 June 2021). "Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers". finance.yahoo.com. Retrieved 2021-06-24.
External links
[edit]
 | This corporation or company article is a stub. You can help Wikipedia by expanding it. |